Parameswaran Venugopal

3.1k total citations
130 papers, 1.9k citations indexed

About

Parameswaran Venugopal is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Parameswaran Venugopal has authored 130 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Hematology, 50 papers in Genetics and 43 papers in Pathology and Forensic Medicine. Recurrent topics in Parameswaran Venugopal's work include Acute Myeloid Leukemia Research (46 papers), Lymphoma Diagnosis and Treatment (42 papers) and Chronic Lymphocytic Leukemia Research (41 papers). Parameswaran Venugopal is often cited by papers focused on Acute Myeloid Leukemia Research (46 papers), Lymphoma Diagnosis and Treatment (42 papers) and Chronic Lymphocytic Leukemia Research (41 papers). Parameswaran Venugopal collaborates with scholars based in United States, India and Poland. Parameswaran Venugopal's co-authors include Azra Raza, Sefer Gezer, Stephanie A. Gregory, Laurie Lisak, Saleem Dar, Harvey D. Preisler, Vilasini Shetty, Suneel Mundle, Fabiana Nascimben and Jerome Loew and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Parameswaran Venugopal

124 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Parameswaran Venugopal United States 21 1.1k 684 482 412 339 130 1.9k
Ryuichi Kamiyama Japan 24 658 0.6× 548 0.8× 270 0.6× 435 1.1× 384 1.1× 75 1.8k
Rajko Kušec Croatia 24 1.0k 1.0× 979 1.4× 887 1.8× 280 0.7× 341 1.0× 104 2.0k
Norifumi Tsukamoto Japan 25 826 0.8× 381 0.6× 561 1.2× 433 1.1× 706 2.1× 139 2.1k
Jamile M. Shammo United States 17 874 0.8× 429 0.6× 587 1.2× 305 0.7× 227 0.7× 79 1.5k
Rudolf Schlag Germany 16 973 0.9× 871 1.3× 808 1.7× 1.0k 2.4× 669 2.0× 60 2.3k
Thomas Cluzeau France 20 1.4k 1.4× 808 1.2× 569 1.2× 309 0.8× 151 0.4× 107 2.0k
Eileen M. Boyle United States 20 592 0.6× 530 0.8× 341 0.7× 444 1.1× 341 1.0× 84 1.5k
Andrea Kündgen Germany 19 2.1k 2.0× 655 1.0× 1.1k 2.2× 231 0.6× 175 0.5× 50 2.4k
Catherine C. Coombs United States 15 800 0.8× 521 0.8× 469 1.0× 287 0.7× 224 0.7× 65 1.4k
Álvaro Aguayo Mexico 19 867 0.8× 933 1.4× 501 1.0× 506 1.2× 202 0.6× 46 1.8k

Countries citing papers authored by Parameswaran Venugopal

Since Specialization
Citations

This map shows the geographic impact of Parameswaran Venugopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Parameswaran Venugopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Parameswaran Venugopal more than expected).

Fields of papers citing papers by Parameswaran Venugopal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Parameswaran Venugopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Parameswaran Venugopal. The network helps show where Parameswaran Venugopal may publish in the future.

Co-authorship network of co-authors of Parameswaran Venugopal

This figure shows the co-authorship network connecting the top 25 collaborators of Parameswaran Venugopal. A scholar is included among the top collaborators of Parameswaran Venugopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Parameswaran Venugopal. Parameswaran Venugopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cahill, Kirk E., James Godfrey, Chadi Nabhan, et al.. (2025). A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Advances. 9(21). 5665–5675.
2.
Strati, Paolo, Morton Coleman, Sonali M. Smith, et al.. (2024). Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open‐label study. British Journal of Haematology. 205(6). 2248–2253. 2 indexed citations
3.
Gezer, Sefer, et al.. (2020). Heparin Induced Thrombocytopenia in Patients with COVID-19. Blood. 136(Supplement 1). 17–18. 8 indexed citations
4.
Hein, Kyaw Zaw, et al.. (2020). Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction. Cardio-Oncology. 6(1). 10–10. 17 indexed citations
5.
Okwuosa, Tochi M., Hena Patel, Timothy M. Kuzel, et al.. (2018). The Cardiologist and the Cancer Patient. Journal of the American College of Cardiology. 72(2). 228–232. 7 indexed citations
6.
Venugopal, Parameswaran, et al.. (2017). Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature. Molecular and Clinical Oncology. 6(4). 539–542. 19 indexed citations
7.
Karmali, Reem, Melissa L. Larson, Jamile M. Shammo, et al.. (2015). Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia. Leukemia & lymphoma. 56(11). 3135–3142. 8 indexed citations
8.
9.
Nabhan, Chadi, Nancy Davis, Jacob D. Bitran, et al.. (2010). Efficacy and safety of clofarabine in relapsed and/or refractory non‐hodgkin lymphoma, including rituximab‐refractory patients. Cancer. 117(7). 1490–1497. 13 indexed citations
10.
Schuster, Stephen J., et al.. (2008). GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leukemia & lymphoma. 49(9). 1681–1692. 13 indexed citations
11.
Saberwal, Gurveen, İmke Janssen, Vilasini Shetty, et al.. (2003). Involvement of Cyclin D1 and E2F1 in Intramedullary Apoptosis in Myelodysplastic Syndromes. Journal of Hematotherapy & Stem Cell Research. 12(4). 443–450. 11 indexed citations
12.
Tao, Min, Yaqin Li, Shiwen Song, et al.. (2001). In VivoEffects of IL-4, IL-10, and Amifostine on Cytokine Production in Patients with Acute Myelogenous Leukemia. Leukemia & lymphoma. 41(1-2). 161–168. 16 indexed citations
13.
Zorat, Francesca, Vilasini Shetty, Laurie Lisak, et al.. (2001). The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. British Journal of Haematology. 115(4). 881–894. 85 indexed citations
14.
Preisler, Harvey D., Parameswaran Venugopal, S. A. Gregory, et al.. (2001). High Remission Rate in Acute Myeloblastic Leukemia with Only Two Days of Chemotherapy. Leukemia & lymphoma. 41(3-4). 333–336. 4 indexed citations
15.
16.
Li, Yaqin, et al.. (2000). Poor prognosis acute myelogenous leukemia 2 — biological and molecular biological characteristics and treatment outcome. Leukemia Research. 24(9). 777–789. 5 indexed citations
17.
Ranganathan, Raghuveer, Xiao‐Jun Huang, Timothy O’Brien, et al.. (2000). Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: A new role for TNF alpha?. Microscopy Research and Technique. 50(3). 251–257. 17 indexed citations
18.
Tao, Min, Yaqin Li, Raywin Huang, et al.. (2000). SCF, IL-1β, IL-1ra AND GM-CSF IN THE BONE MARROW AND SERUM OF NORMAL INDIVIDUALS AND OF AML AND CML PATIENTS. Cytokine. 12(6). 699–707. 29 indexed citations
19.
Mundle, Suneel, Ambereen Ali, Vilasini Shetty, et al.. (1999). Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Letters. 140(1-2). 201–207. 53 indexed citations
20.
Dar, Saleem, Suneel Mundle, Vilasini Shetty, et al.. (1999). Biologic Characteristics of 164 Patients with Myelodysplastic Syndromes. Leukemia & lymphoma. 33(3-4). 281–287. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ryuichi Kamiyama Breakdown of academic impact, for papers by Rajko Kušec Breakdown of academic impact, for papers by Norifumi Tsukamoto Breakdown of academic impact, for papers by Jamile M. Shammo Breakdown of academic impact, for papers by Rudolf Schlag Breakdown of academic impact, for papers by Thomas Cluzeau Breakdown of academic impact, for papers by Eileen M. Boyle Breakdown of academic impact, for papers by Andrea Kündgen Breakdown of academic impact, for papers by Catherine C. Coombs Breakdown of academic impact, for papers by Álvaro Aguayo
Rankless by CCL
2026